NCT03117634 - An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

June 30, 2020

Study Completion Date

January 31, 2021

Conditions

Age Related Macular DegenerationPolypoidal Choroidal Vasculopathy

Interventions

DRUG

Treat and Extend with Aflibercept 2mg

Drug treatment regime which allows extension of treatment interval based on disease activity

DRUG

Fixed Dosing with Aflibercept 2mg

Fixed 8 weekly dosing regime throughout the study duration

Trial Locations (1)

Singapore National Eye Centre, Singapore